Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?
Patients can enroll if they:
Patients will be excluded if they:
Contact: John Glaspy, MD 310-794-0066 email@example.com
Contact: Christy Palodichuk 310-794-2971 Cpalodichuk@mednet.ucla.edu
The purpose of the study is to determine the best dosing schedule for the oral drug CC-486 (oral azacitidine) in combination with the immuno-oncology agent pembrolizumab (Keytruda) for the treatment of platinum-resistant/refractory Epithelial Ovarian Cancer (EOC).
This is an open-label, non-randomized, four-cohort study.